#hydroxyurea
World Cervical Cancer Elimination Day: Awareness for a Healthier Tomorrow

Visit here:- www.oddwayinternational.com/hydroxyurea-...

#CervicalCancer #HPVVaccination #HealthAwareness #OddwayInternational #CancerPrevention
November 17, 2026 at 9:20 AM
This just in JHC: "Immunocytochemical Localization of Neuronal Nitric Oxide Synthase (nNOS) in Neutrophils: Hydroxyurea Therapy Induced Nucleo-Cytoplasmic Translocation in Sickle Cell Disease."

Click to read: journals.sagepub.com/doi/abs/10.1...

#immunolocalization #immunocytochemistry
November 9, 2026 at 7:52 PM
Ophthopedia Update: Response to “Hydroxyurea and sickle cell retinopathy: Why association should not be interpreted as prevention”: Dear Editor, #Ophthalmology #Eye #Ophthotwitter
Response to “Hydroxyurea and sickle cell retinopathy: Why association should not be interpreted as prevention”
Dear Editor,
dlvr.it
October 22, 2026 at 3:16 AM
Ophthopedia Update: Hydroxyurea and Sickle Cell Retinopathy: Why Association Should Not Be Interpreted as Prevention: Dear Editor #Ophthalmology #Eye #Ophthotwitter
Hydroxyurea and Sickle Cell Retinopathy: Why Association Should Not Be Interpreted as Prevention
Dear Editor
dlvr.it
October 21, 2026 at 3:17 PM
This just in JHC: "Immunocytochemical Localization of Neuronal Nitric Oxide Synthase (nNOS) in Neutrophils: Hydroxyurea Therapy Induced Nucleo-Cytoplasmic Translocation in Sickle Cell Disease."

Click to read: journals.sagepub.com/doi/abs/10.1...

#immunolocalization #microscopy
October 19, 2026 at 8:43 PM
Screening is the first step. Transcranial Doppler screening for stroke risk and early hydroxyurea are what turn a diagnosis into fewer strokes and deaths.
October 19, 2026 at 4:00 AM
ET trials have moved beyond aspirin plus hydroxyurea: ropeginterferon, the LSD1 inhibitor bomedemstat and mutant-CALR antibodies all target the disease, not just the platelet count. The open question is which end point (molecular response, thrombosis, or MF progression) regulators will accept.
October 15, 2026 at 7:21 PM
In a European study, the majority of patients with homozygous #SCD who were prescribed #hydroxyurea had undetectable blood levels of the drug, especially those younger than 10 years, suggesting ongoing challenges in treatment implementation and adherence: https://ow.ly/YAvv50ZY0mZ
October 15, 2026 at 2:15 PM
A Cincinnati Children's led study, recently published in The Lancet Haematology, found that long-term data from the REACH trial show hydroxyurea safely treats children with #sicklecell anemia in Africa without increasing the risk of serious infections, expanding access to care.
Children Living With Sickle Cell Can Be Treated Safely Using Hydroxyurea - Research Horizons
Long-term REACH trial data show hydroxyurea safely treats children with sickle cell anemia in Africa without increasing serious infections.
scienceblog.cincinnatichildrens.org
October 9, 2026 at 1:52 PM
Ten years of hydroxyurea treatment did not increase infections in children with sickle cell anemia at four African sites—even at the maximum tolerated dose.
Children living with sickle cell can be treated safely using hydroxyurea, 10-year trial finds
New research shows the efficacy and safety of hydroxyurea treatment for sickle cell anemia at four low-income sites in Africa, with no increase in clinically diagnosed infections.
medicalxpress.com
October 7, 2026 at 10:30 PM
Hydroxyurea does not increase infection risk in children with sickle cell anemia
Children living with sickle cell anemia have no higher incidence of clinically diagnosed infections when treated with hydroxyurea. New research shows the efficacy and safety of hydroxyurea treatment for sickle cell anemia, in four low-income sites in Africa, with no increase in clinically diagnosed infections. Hydroxyurea is a drug taken once daily by mouth that works to reduce the complications of sickle cell anemia by encouraging the body to produce more fetal hemoglobin, the form of hemoglobin normally made by babies in the womb, that stops red blood cells from sickling. While hydroxyurea is recommended treatment in high-income countries, doctors have been cautious in low-income settings, because it reduces the number of infection-fighting neutrophils, and could therefore lead to an increased risk of infections where access to clinical services is low. The study, part of the NIH-funded Realizing Effectiveness Across Continents with Hydroxyurea, (REACH) trial, showed that in fact there was no increase in the incidence or severity of infections, including malaria, in children receiving hydroxyurea treatment. Living with sickle cell Sickle cell anemia is the most common and severe inherited blood disease in humans, with approximately 80% of cases occurring in sub-Saharan Africa. Around 550,000 children are born with...
www.news-medical.net
October 8, 2026 at 7:22 AM
A study from the American Journal of Hematology reveals that blood levels of hydroxyurea - the most commonly prescribed disease-modifying treatment in #SickleCellDisease - were undetectable in the majority of patients 🩸

@ashclinicalnews.bsky.social dives into the findings: https://bit.ly/4yItqqK
October 8, 2026 at 1:00 PM
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
vTv Therapeutics (Nasdaq: VTVT) received FDA Orphan Drug Designation for HPPD, its investigational oral treatment for sickle cell disease.Preclinical studies at Augusta University used the Townes sickle cell disease mouse model. HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced oxidative stress and red blood cell sickling. Fetal hemoglobin increases were time- and dose-dependent, with effects comparable to or exceeding hydroxyurea, the current standard fetal hemoglobin-inducing therapy.vTv said the designation supports partnering discussions for HPPD while it continues to prioritize cadisegliatin, its lead late-stage type 1 diabetes program. HPPD remains investigational; its safety and efficacy have not been established, and approval or commercial availability is not guaranteed.
www.stocktitan.net
October 7, 2026 at 8:01 PM
This just in JHC: "Immunocytochemical Localization of Neuronal Nitric Oxide Synthase (nNOS) in Neutrophils: Hydroxyurea Therapy Induced Nucleo-Cytoplasmic Translocation in Sickle Cell Disease."

Click to read: journals.sagepub.com/doi/abs/10.1...

#immunolocalization #microscopy #immunocytochemistry
September 30, 2026 at 9:46 PM
From taking hydroxyurea as a child to participating in clinical studies as an adult, longtime Johns Hopkins Medicine patient and advocate Aldoris Mbonya-Bate has seen decades of progress in sickle cell treatment firsthand. | Hub hub.jhu.edu/2026/09/24/s...
A patient's experience with the evolution of sickle cell disease treatment
From taking hydroxyurea as a child to participating in clinical studies as an adult, longtime Johns Hopkins Medicine patient and advocate Aldoris Mbonya-Bate has seen decades of progress in sickle cel...
hub.jhu.edu
September 25, 2026 at 3:21 PM
In SC-HU (synthetic complete media with hydroxyurea), there seemed to be several alternative states where one of three strains dominated in different replicates:
September 22, 2026 at 6:34 PM
In SC-HU (synthetic complete media with hydroxyurea), there seemed to be several alternative states where one of three strains dominated in different replicates:
September 22, 2026 at 6:13 PM
In SC-HU (synthetic complete media with hydroxyurea), there seemed to be several alternative states where one of three strains dominated in different replicates:
September 22, 2026 at 5:44 PM
Sickle Cell Disease Care in Jamaica: Enablers and Barriers to Healthcare Access and Hydroxyurea Utilization https://www.medrxiv.org/content/10.64898/2026.09.16.26363231v1
September 18, 2026 at 4:55 AM
(BioRxiv All) Temporal proximity proteomics reveals ANP32A roles in replication fork progression and end joining: Acidic nuclear phosphoprotein 32 family member A (ANP32A) regulates chromatin and histone homeostasis, but its contribution to DNA replication and repair remains… #BioRxiv #MassSpecRSS
Temporal proximity proteomics reveals ANP32A roles in replication fork progression and end joining
Acidic nuclear phosphoprotein 32 family member A (ANP32A) regulates chromatin and histone homeostasis, but its contribution to DNA replication and repair remains unclear. Time-resolved AirID proximity labeling with data-independent acquisition mass spectrometry revealed phased remodeling of the ANP32A proximal proteome during hydroxyurea-induced replication stress. Early stress enriched DNA replication and repair factors, including FEN1, XRCC5/Ku80, and XRCC6/Ku70, whereas prolonged exposure shifted the network towards checkpoint and cell-cycle regulators. Orthogonal proximity ligation assays revealed sustained ANP32A-FEN1 proximity and transiently increased ANP32A-XRCC5 proximity. ANP32A was dynamically recruited to {gamma}H2AX-marked lesions following laser microirradiation and showed increased proximity to {gamma}H2AX after hydroxyurea treatment. ANP32A loss impaired proliferation and G1/S progression and moderately reduced replication fork velocity. However, it did not promote nascent strand degradation at stalled forks or measurably alter homologous recombination reporter activity. In contrast, ANP32A loss reduced non-homologous end-joining reporter activity, consistent with its stress-induced proximity to Ku proteins. These findings identify ANP32A as a chromatin-associated factor supporting replication fork progression and end joining while dispensable for stalled-fork protection, linking ANP32A-dependent chromatin regulation to genome maintenance.
dlvr.it
September 15, 2026 at 4:06 PM
Teranga Pharma launched its own version of generic hydroxyurea, considered the gold standard in sickle cell treatment, and has begun supplying pharmacies across the country.
www.semafor.com/newsletter/0...
🟡 Semafor Africa: ‘We will go home’ | Semafor
In this edition: South Africa’s GDP shrinks, Nigeria’s trade surplus doubles, and Kenya’s foreign traders fear a crackdown.
www.semafor.com
September 9, 2026 at 8:12 PM
Senegal has started producing a locally manufactured generic version of hydroxyurea, a medicine used to treat sickle cell disease.

The medicine, known as Drepaf, is being produced by local Senegalese pharmaceutical company Teranga Pharma.

It is the continent’s first treatment for sickle cell.
September 6, 2026 at 6:56 PM
New research by Kristin Guilliams, MD, and colleagues, published in Brain Research Bulletin, suggests that earlier and longer treatment of children with sickle cell anemia with hydroxyurea was linked to better gray matter and total brain volume.
https://bit.ly/3TVoaQY
September 2, 2026 at 8:15 PM
FDA today (8/31) expanded BESREMi (ropeginterferon alfa-2b) to adults with essential thrombocythemia. SURPASS-ET (NCT04285086): 174 after hydroxyurea; durable modified ELN response 37.4% vs 3.6% on anagrelide at months 9 and 12. Not medical advice. https://corterve.com #ClinicalTrials #MPN
August 31, 2026 at 9:09 PM